 Lung cancer is actually, it's a very prevalent disease. It's the most common cause of cancer related death, but there's been tremendous strides made. When I started in this field, it was very frustrating because patients were blamed for their disease. A lot of the patients, 80% of the patients, used tobacco products. And I always thought that was very unfair because a lot of diseases have lifestyle related issues, whether it's coronary artery disease, whether it's something there. So lung cancer patients being singled out, I thought it wasn't fair and that's one of the reasons I went into this field. Lung cancer used to be more or less a death sentence and so much exciting stuff has happened, specifically with immune based therapy. The latest data that's coming out in the olden days and by olden days I mean about a year ago, we were able to offer curative surgical resection to maybe 15, 20% of patients. Now with giving immune therapy up front, we can actually shrink tumors and surgically cure tumors substantially higher number of patients. It's only going to get bigger and bigger. This is very exciting new data. We offer a very robust lung cancer resection program in conjunction with our medical oncologists where a lot of our patients will get chemotherapy up front with immunotherapy up front, shrink the tumor and then they can go undergo a minimally invasive resection, whether it's robotic or video-assisted with a very, very short length of stay measured in days, sometimes even hours. So this is a very, very exciting development. Obviously, the treatment for the disease will get better and better. Smoking cessation efforts occur. But again, 20% of patients who get lung cancer are considered never smokers and it's still one of the most common cancers out there. So we don't know why air pollution, some of the things in the environment. But our lung cancer program is very robust as far as FDA approved treatment, clinical trials as well as basic research of understanding the fundamentals of how lung cancer develops and progresses. Our goal is to have a zero percent mortality for anybody with lung cancer.